



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K		A2	(11) International Publication Number: WO 00/00156 (43) International Publication Date: 6 January 2000 (06.01.00)
<p>(21) International Application Number: PCT/US99/12825</p> <p>(22) International Filing Date: 25 June 1999 (25.06.99)</p> <p>(30) Priority Data: 60/090,849 26 June 1998 (26.06.98) US</p> <p>(71) Applicant (<i>for all designated States except US</i>): TRUSTEES OF DARTMOUTH COLLEGE [US/US]; 11 Rope Ferry Road #6210, Hanover, NH 03755-1404 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (<i>for US only</i>): WADE, William, F. [US/US]; Dartmouth Medical School, Dept. of Microbiology, 603 W. Borwell Building, One Medical Center Drive, Lebanon, NH 03756 (US). DEMIAN, Douglas [US/US]; Dartmouth Medical School, Dept. of Microbiology, 603 W. Borwell Building, One Medical Center Drive, Lebanon, NH 03756 (US).</p> <p>(74) Agent: TESKIN, Robin, L.; Burns, Doane, Swecker & Mathis, L.L.P., P.O. Box 1404, Alexandria, VA 22313-1404 (US).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>	
<p>(54) Title: METHODS AND COMPOSITIONS FOR MODULATING ANTIGEN-SPECIFIC IMMUNOLOGICAL (HUMORAL) RESPONSES BY TARGETING SUCH ANTIGEN TO APCs IN CONJUNCTION WITH ANTI-CD40 LIGAND ADMINISTRATION</p> <p>(57) Abstract</p> <p>Methods and compositions are provided which upon administration to a subject in need of such treatment result in enhanced or suppressed immunological responses and in particular enhanced or suppressed humoral (antibody) immune responses to a desired antigen. These methods and compositions include an antigen directly or indirectly attached to an antibody specific for antigen expressed by an antigen-presenting cell and optionally an anti-CD40 antibody. These methods and compositions are particularly useful in the treatment of infectious diseases, such as viral, bacterial or fungal infection, and the treatment and/or prevention of cancer, especially for treatment of aged individuals or other subjects having impaired immune systems, and the treatment of autoimmune diseases, transplant, allergy, inflammatory diseases, wherein suppression of antigen-specific immune response is therapeutically beneficial.</p>			